SCHEMBL7216356

SCHEMBL7216356

CCOCCCc1ccc(Oc2ccc3c(c2)C=C(C(=O)OC)CCS3(=O)=O)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.34
CYP4A11 Q02928 2/20 0.33
CYP4F2 P78329 1/20 0.32
MDH1 P40925 2/20 0.32
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32
PPARG P37231 1/20 0.31
CA12 O43570 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
THRA P10827 2/20 0.31
THRB P10828 2/20 0.31
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7221932 0.91 PPARG (0.34) KDM4EADRB2ADRB1ADRB3PPARG
SCHEMBL7215982 0.88 ACACB (0.36) MDH1CA12CA2CA9THRB
SCHEMBL7221547 0.85 LMNA (0.40) MDH1SMN1; SMN2L3MBTL1RAB9AGPR119
SCHEMBL7216635 0.82 LTA4H (0.39) KDM4ECA12CA2CA9THRB
SCHEMBL7223588 0.82 THRB (0.33) KDM4ECA12CA2CA9THRA
SCHEMBL7222803 0.81 NPC1 (0.38) KDM4EPPARGHPGDSMN1; SMN2L3MBTL1
SCHEMBL7216131 0.81 MAPT (0.36) KDM4ECA12CA2CA9SMN1; SMN2
SCHEMBL7222347 0.78 ACACB (0.35) PPARGTHRATHRBRAB9AALDH1A1
SCHEMBL7968606 0.78 MAPT (0.36) KDM4ETHRAHPGDRAB9AGPR119
SCHEMBL7218066 0.78 NPC1 (0.41) KDM4EHPGDSMN1; SMN2L3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed